Kingdon Capital Management’s Praxis Precision Medicines PRAX Stock Holding History

Kingdon Capital Management’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-303,000	Closed	-$23.3M	–	88
2024 Q4	$23.3M	Sell	303,000 -65,000	-18%	-$4.7M	3.32%	3
2024 Q3	$21.2M	Sell	368,000 -47,000	-11%	-$2.54M	2.35%	7
2024 Q2	$17.2M	Buy	415,000 +65,000	+19%	+$3.07M	1.84%	15
2024 Q1	$21.4M	Buy	350,000 +3,335	+1%	+$150K	2.33%	5
2023 Q4	$7.72M	Sell	346,665 -2	-0%	-$36	0.97%	40
2023 Q3	$8.89M	Hold	346,667	–	–	1.02%	39
2023 Q2	$5.98M	Buy	346,667 +33,334	+11%	+$510K	0.57%	50
2023 Q1	$3.8M	Buy	313,333 +122,934	+65%	+$5.19M	0.72%	47
2022 Q4	$6.8M	Buy	190,399 +113,333	+147%	+$3.53M	1.35%	31
2022 Q3	$2.62M	Hold	77,066	–	–	0.34%	44
2022 Q2	$2.83M	Buy	77,066 +49,433	+179%	+$5.28M	0.48%	49
2022 Q1	$4.23M	Hold	27,633	–	–	0.44%	51
2021 Q4	$8.16M	Hold	27,633	–	–	0.94%	37
2021 Q3	$7.66M	Buy	27,633 +10,966	+66%	+$2.97M	0.93%	34
2021 Q2	$4.57M	Buy	+16,667	New	+$5.97M	0.53%	49

Other funds holding PRAX

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Kingdon Capital Management's PRAX Position: Q1 2025 in Review

Kingdon Capital Management sold out of Praxis Precision Medicines (PRAX) in Q1 2025, closing a stake of 303,000 shares — an estimated $23.3M sold.

Kingdon Capital Management first reported a position in PRAX in Q2 2021 and held it in 15 quarters. The position peaked at $23.3M in Q4 2024. 150 funds tracked by Wall St. Rank hold PRAX as of Q1 2025.

Kingdon Capital Management reported no remaining Praxis Precision Medicines position as of Q1 2025 after selling out during the quarter.
Kingdon Capital Management sold 303,000 Praxis Precision Medicines shares in Q1 2025, an estimated $23.3M.
Kingdon Capital Management first reported a position in Praxis Precision Medicines in Q2 2021 and held it in 15 quarters.
Kingdon Capital Management's Praxis Precision Medicines position peaked at $23.3M in Q4 2024.
150 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q1 2025.

Based on Kingdon Capital Management's 13F filing for Q1 2025, filed 15 May 2025.